Efficacy of tadalafil on symptom-specific bother in men with lower urinary tract symptoms

This multicenter and prospective study was performed to evaluate the efficacy of tadalafil on patient-reported bother for each symptom in men with lower urinary tract symptoms (LUTS).Men with LUTS received 5 mg of tadalafil daily for 4 weeks. We assessed change in symptom severity using both international prostate symptom score (IPSS), and overactive bladder symptom score (OABSS), as well as patient-reported quality of life (QOL: bother or satisfaction) for each symptoms using IPSS-visual analog scale (IPSS-VAS) and OABSS-VAS.We found significant improvements in total IPSS (P 0.001), including voiding symptoms (P 0.001), storage symptoms (P 0.001), and QOL (P 0.001). All VAS measures corresponding to symptoms in IPSS and OABSS also significantly improved (P 0.001). The most bothersome symptoms for each patient at baseline evaluated by VAS measures significantly improved (P 0.001). Patients whose most bothersome symptoms at baseline included IPSS-Q7 (nocturia) showed significantly smaller improvement of VAS measure after treatment than those without it (P = 0.024).Daily tadalafil significantly improved not only symptom severity of LUTS but also patient-reported QOL on each symptom.